Cytokinetics
Biopharmaceutical company focused on discovery, development, and commercialization of small-molecule therapies that modulate sarcomere proteins to treat diseases of impaired muscle function (cardiac and neuromuscular). Activities include preclinical research, clinical development (Phases 1–3), regulatory submissions and interactions with global agencies, and medical affairs support for healthcare professionals.
Industries
Nr. of Employees
large (251-1000)
Cytokinetics
South San Francisco, California, United States
Patents
Polymorphs of (R)-N-(5-(5-isopropyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-2-methyl-2H-tetrazole-5-carboxamide
US-12649732-B2
View Details
Polymorphs of (R)-N-(5-(5-isopropyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-2-methyl-2H-tetrazole-5-carboxamide
US-12649732-B2
View DetailsProducts
Investigational small-molecule sarcomere modulators (cardiac myosin modulators and troponin activators/inhibitors)
Pipeline of investigational small molecules designed to modulate sarcomere proteins to increase or decrease muscle contractility for treatment of cardiac and neuromuscular diseases. Includes oral and intravenous formulations evaluated in clinical trials.
CK-4015089
A fast skeletal muscle troponin activator in early-stage clinical trials.
CK-4021586
A next-generation cardiac myosin inhibitor in clinical development.
MYQORZO
An approved and commercialized medicine for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms.
aficamten
A selective cardiac myosin inhibitor developed for the treatment of hypertrophic cardiomyopathy (HCM), including symptomatic obstructive HCM (oHCM) and non-obstructive HCM (nHCM).
ulacamten
A cardiac sarcomere modulator being investigated in clinical trials for patients with symptomatic heart failure with preserved ejection fraction (HFpEF).
Investigational small-molecule sarcomere modulators (cardiac myosin modulators and troponin activators/inhibitors)
Pipeline of investigational small molecules designed to modulate sarcomere proteins to increase or decrease muscle contractility for treatment of cardiac and neuromuscular diseases. Includes oral and intravenous formulations evaluated in clinical trials.
CK-4015089
A fast skeletal muscle troponin activator in early-stage clinical trials.
CK-4021586
A next-generation cardiac myosin inhibitor in clinical development.
MYQORZO
An approved and commercialized medicine for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms.
aficamten
A selective cardiac myosin inhibitor developed for the treatment of hypertrophic cardiomyopathy (HCM), including symptomatic obstructive HCM (oHCM) and non-obstructive HCM (nHCM).
ulacamten
A cardiac sarcomere modulator being investigated in clinical trials for patients with symptomatic heart failure with preserved ejection fraction (HFpEF).
Services
Channels for US healthcare providers to submit unsolicited medical information requests and receive educational responses.
Channels for US healthcare providers to submit unsolicited medical information requests and receive educational responses.
Expertise Areas
- Muscle biology drug discovery
- Sarcomere-directed therapeutics
- Clinical trial management (Phase 1–3)
- Cardiovascular (heart failure, HCM) clinical development
Key Technologies
- Small-molecule drug discovery
- Cardiac myosin modulation
- Troponin modulation
- In vivo disease models
News & Updates
Clinical trial results from pivotal studies have been published in peer-reviewed journals including the New England Journal of Medicine (e.g., GALACTIC-HF).
Corporate presentation summarizing mission, pipeline and clinical development.
Received FDA approval for the company's first medicine.
Received positive CHMP opinion and national approval in China for a sarcomere-directed therapy.
Announced positive results from pivotal Phase 3 trials (e.g., SEQUOIA-HCM) with simultaneous publication in peer-reviewed journals.
Clinical trial results from pivotal studies have been published in peer-reviewed journals including the New England Journal of Medicine (e.g., GALACTIC-HF).
Corporate presentation summarizing mission, pipeline and clinical development.
Received FDA approval for the company's first medicine.
Received positive CHMP opinion and national approval in China for a sarcomere-directed therapy.
Announced positive results from pivotal Phase 3 trials (e.g., SEQUOIA-HCM) with simultaneous publication in peer-reviewed journals.